Skip to main content
We will be working on site updates on Wednesday, July 26. The platform should operate normally for most of the day, except for a 2-4 hour long disruption during maintenance. We apologize for any inconvenience.
3.145.167.152

Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination

By Bottecchia, Cecilia; Lévesque, François; McMullen, Jonathan P.; Ji, Yining; Reibarkh, Mikhail; Peng, Feng; Tan, Lushi; Spencer, Glenn; Nappi, Jarod; Lehnherr, Dan; Narsimhan, Karthik; Wismer, Michael K.; Chen, Like; Lin, Yipeng; Dalby, Stephen M.

View Resource (DOI)

Category

Peer-reviewed journal

Published on CMKC

Abstract

We report the development and scale-up of a continuous flow photochemical benzylic bromination en route to belzutifan (MK-6482), a small molecule for the treatment of renal cell carcinoma associated with Von Hippel–Lindau syndrome. Compared with the clinical supply route, the photochemical approach circumvents the need for azo radical initiators and proceeds at room temperature. Implementation of continuous flow technology allowed tight control of irradiation and residence time, resulting in a robust process with minimized byproduct formation. This method was selected for the manufacturing process for belzutifan and represents the first commercial continuous flow photochemical process in our company, laying the foundation for the utilization of photochemistry in the pharmaceutical industry.

Journal

Organic Process Research & Development. Volume 26, 2022, 516–524

DOI

10.1021/acs.oprd.1c00240

Type of publication

Peer-reviewed journal

Affiliations

  • Merck & Co., Inc.
  • Shanghai SynTheAll Pharmaceutical Co. Ltd.

Article Classification

Research Article

Classification Areas

  • Intermediate

Tags

  1. Belzutifan
  2. Intermediate
  3. photobromination
  4. photochemical
  5. renal cell carcinoma
  6. Research Article
  7. Scale-up